Progyny(NASDAQ) PGNY

Current Price$31.13

Market Cap$2.44B

Since IPO (2019)+96%

5 Year-45%

1 Year+36%

1 Month+16%

Progyny last closing stock price
Metric	Price	Date
Last close	USD 31.19	2026-07-24

Progyny stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.32%	USD 31.93	2026-07-17
1 month	+15.99%	USD 26.89	2026-06-24
3 month	+71.66%	USD 18.17	2026-04-24
Year to date	+21.46%	USD 25.68	2025-12-31
1 year	+35.61%	USD 23.00	2025-07-24
3 year	-20.8%	USD 39.38	2023-07-25
5 year	-44.89%	USD 56.60	2021-07-23
Since inception	+95.67%	USD 15.94	2019-10-25

Progyny Financials at a Glance

Market Cap

$2.44B

Revenue (TTM)

$1.29B

Net Income (TTM)

$67.69M

EPS (TTM)

$0.77

P/E Ratio

40.51

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$31.13

Volume

644,560.538

Open

$31.45

Price

$31.13

Volume

644,560.538

Open

$31.45

Previous Close

$31.19

Daily Range

$30.83 - $31.73

52-Week Range

$16.10 - $33.07

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$31.13

Volume

644,560.538

Open

$31.45

Previous Close

$31.19

Daily Range

$30.83 - $31.73

52-Week Range

$16.10 - $33.07

Estimated Earnings Date

Aug 6, 2026

PGNY News

Progyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for Investors

Josh Kohn-LindquistJul 19, 2026

Page 1

PGNY: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Progyny

Progyny helps people have children by managing their health benefits. It connects workers to top doctors and fertility treatments. This makes starting a family easier and more affordable for employees.

Treatments and Pharmacy Support

Fertility Benefits: Plan designs called Smart Cycles that bundle medical services for fertility treatments; generated $209.4 million in revenue for Q1 2026.
Progyny Rx: Integrated pharmacy service providing medications needed for family building procedures; generated $119.1 million in revenue for Q1 2026.
Concierge Support: Personalized guidance from advocates who help members navigate complex medical and insurance journeys.
Expanded Health Solutions: Services covering menopause and midlife health to support women through different life stages.

Strategic Deals and Growing Networks

Acquired Benefit Bump LLC in January 2025 to add parental leave and return-to-work navigation services.
Expanded the platform in early 2025 to include menopause, pregnancy, and child wellbeing solutions.
Entered a $200 million revolving credit facility in July 2025 to support general business needs.
Increased the total client count to 595 employers by March 2026, up from 555 at the end of 2025.

What Sets the Model Apart

Progyny uses a data-driven model that delivers clinical outcomes, such as higher live birth rates, compared to national averages. Its selective network and personalized support have maintained high satisfaction scores from both members and employer clients.

Checking the Financial Pulse

Revenue reached $328.5 million in Q1 2026, up 1.4% from the $324.0 million reported in Q1 2025.
Net income rose to $24.2 million in Q1 2026, a 60.9% increase from $15.1 million in the prior year.
Operating income reached $35.4 million in Q1 2026, up 46.4% from the $24.2 million earned in Q1 2025.
Free cash flow was $39.6 million for the period ended March 31, 2026, down 15.7% year-over-year.

Bottom Line

Progyny has evolved from a specialized fertility provider into a broader platform for women's health and family building. This expansion and a growing list of corporate clients have helped the company increase its operational profitability.

AI Generated • May 26, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

856

CEO

Peter Anevski

Website

www.progyny.com

Headquarters

New York City, NY 10018, US

PGNY Financials

Key Financial Metrics (TTM)

Gross Margin

24.11%

Operating Margin

7.46%

Net Income Margin

5.23%

Return on Equity

13.34%

Return on Capital

15.68%

Return on Assets

9.69%

Earnings Yield

2.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.44B

Shares Outstanding

78.33M

Volume

644.56K

Avg. Volume

1.48M

Financials (TTM)

Gross Profit

$311.76M

Operating Income

$96.49M

EBITDA

$111.10M

Operating Cash Flow

$206.33M

Capital Expenditure

-$21.91M

Free Cash Flow

$184.42M

Cash & ST Invst.

$226.15M

Total Debt

$27.28M

Progyny Performance Analysis

Progyny annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 786,913,000	57.2%
2023	2023-12-31	USD 1,088,598,000	38.3%
2024	2024-12-31	USD 1,167,221,000	7.2%
2025	2025-12-31	USD 1,288,661,000	10.4%

Progyny sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	2.7%
Q3	2025-09-30	-5.9%
Q4	2025-12-31	1.6%
Q1	2026-03-31	3.2%

Progyny annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 0.30	-53.7%
2023	2023-12-31	USD 0.62	102.9%
2024	2024-12-31	USD 0.57	-7.6%
2025	2025-12-31	USD 0.65	14.4%

Progyny sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	11.8%
Q3	2025-09-30	-21.1%
Q4	2025-12-31	-6.7%
Q1	2026-03-31	107.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$328.50M

+1.4%

Gross Profit

$83.07M

+9.6%

Gross Margin

25.29%

N/A

Market Cap

$2.44B

N/A

Market Cap/Employee

$2.85M

N/A

Employees

856

N/A

Net Income

$24.23M

+60.9%

EBITDA

$38.37M

+38.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$226.15M

-11.7%

Total Debt

$27.28M

+4.9%

Accounts Receivable

$263.61M

-12.1%

Inventory

$0.00

N/A

Long Term Debt

$23.25M

-10.6%

Short Term Debt

$4.03M

N/A

Return on Assets

9.69%

N/A

Return on Invested Capital

20.86%

N/A

Free Cash Flow

$39.60M

-15.7%

Operating Cash Flow

$45.95M

-7.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SEMSelect Medical Holdings Corporation

SEMSelect Medical Holdings Corporation$16.51-0.09%

OMCLOmnicell, Inc.

OMCLOmnicell, Inc.$41.00+2.86%

UFPTUFP Technologies, Inc.

UFPTUFP Technologies, Inc.$237.20+0.42%

TDOCTeladoc Health, Inc.

TDOCTeladoc Health, Inc.$8.77+1.27%

OMDAOmada Health

OMDAOmada Health$20.53-3.16%

SDGRSchrödinger, Inc.

SDGRSchrödinger, Inc.$14.97-1.06%

ALVOAlvotech

ALVOAlvotech$3.06-3.77%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

Questions About PGNY

What is the current price of Progyny?

Progyny is trading at $31.19 per share.

What is the 52-week range for Progyny?

Over the past 52 weeks, Progyny has traded between $16.10 and $33.07.

How much debt does Progyny have?

As of the most recent reporting period, Progyny reported total debt of $27.28M.

How much cash does Progyny have on hand?

Progyny reported $132.65M in cash and cash equivalents in its most recent financial results.

What is Progyny’s dividend yield?

Progyny does not currently have a dividend yield.

Progyny(NASDAQ) PGNY

Progyny Financials at a Glance

PGNY News

Progyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for Investors

What Does the Sale of Progyny Shares by the CFO Mean for Investors?

A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000

CEO Peter Anevski Buys $1.9 Million of Progyny Stock: Should Investors Buy Too?

Why Progyny Stock Is Soaring Today

Progyny Tops EPS Forecast, Eyes Growth

Why Progyny Stock Crashed Today

Why Progyny Stock Is Crashing Today

PGNY: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Progyny

Treatments and Pharmacy Support

Strategic Deals and Growing Networks

What Sets the Model Apart

Checking the Financial Pulse

Bottom Line

PGNY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Progyny Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PGNY

What is the current price of Progyny?

What is the 52-week range for Progyny?

How much debt does Progyny have?

How much cash does Progyny have on hand?

What is Progyny’s dividend yield?

Premium Investing Services